Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Tax Provisions (2021 - 2022)

Historic Tax Provisions for Cartesian Therapeutics (RNAC) over the last 2 years, with Q4 2022 value amounting to -$288000.0.

  • Cartesian Therapeutics' Tax Provisions fell 30869.57% to -$288000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $15.4 million, marking a year-over-year decrease of 381.44%. This contributed to the annual value of $287000.0 for FY2024, which is 10151.05% up from last year.
  • As of Q4 2022, Cartesian Therapeutics' Tax Provisions stood at -$288000.0, which was down 30869.57% from -$321000.0 recorded in Q3 2022.
  • In the past 5 years, Cartesian Therapeutics' Tax Provisions ranged from a high of $15.8 million in Q3 2021 and a low of -$321000.0 during Q3 2022